Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study

por Abdelaziz, Lobna A., Taha, Heba F., Ali, Magid M., Abdelgawad, Marwa I., Elwan, Amira
Publicado 2021